Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Should variants of unknown significance (VUS) be disclosed to patients in cardiogenetics or not; only in case of high suspicion of pathogenicity?

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Current and proposed strategy for dealing with VUS-es in cardiogenetics.


  1. van Lint FHM, Mook ORF, Alders M, Bikker H, Lekanne Dit Deprez RH, Christiaans I. Large next-generation sequencing gene panels in genetic heart disease: yield of pathogenic variants and variants of unknown significance. Neth Heart J. 2019;27:304–9.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Morales A, Hershberger RE. Variants of uncertain significance: should we revisit how they are evaluated and disclosed? Circ Genom Precis Med. 2018;11:e002169.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Giudicessi JR, Lieve KVV, Rohatgi RK, Koca F, Tester DJ, van der Werf C, et al. Assessment and validation of a phenotype-enhanced variant classification framework to promote or demote RYR2 missense variants of uncertain significance. Circ Genom Precis Med. 2019;12:e002510.

    Article  CAS  PubMed  Google Scholar 

  4. Ellard S, Baple EL, Callaway A, Berry I, Forrester N, Turnbull C, et al. 2020. ACGS best practice guidelines for variant classification in rare disease 2020.

  5. Arbustini E, Behr ER, Carrier L, van Duijn C, Evans P, Favalli V, et al. Interpretation and actionability of genetic variants in cardiomyopathies: a position statement from the European Society of Cardiology Council on cardiovascular genomics. Eur Heart J. 2022;43:1901–16.

    Article  PubMed  Google Scholar 

  6. Muller RD, McDonald T, Pope K, Cragun D. Evaluation of clinical practices related to variants of uncertain significance results in inherited cardiac arrhythmia and inherited cardiomyopathy genes. Circ Genom Precis Med. 2020;13:e002789.

    Article  PubMed  Google Scholar 

  7. Wilde AAM, Semsarian C, Márquez MF, Sepehri Shamloo A, Ackerman MJ, Ashley EA, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus statement on the state of genetic testing for cardiac diseases. Heart Rhythm. 2022;19:e1–e60.

    Article  PubMed  Google Scholar 

  8. Burns C, Yeates L, Spinks C, Semsarian C, Ingles J. Attitudes, knowledge and consequences of uncertain genetic findings in hypertrophic cardiomyopathy. Eur J Hum Genet. 2017;25:809–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Wong EK, Bartels K, Hathaway J, Burns C, Yeates L, Semsarian C, et al. Perceptions of genetic variant reclassification in patients with inherited cardiac disease. Eur J Hum Genet. 2019;27:1134–42.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Deignan JL, Chung WK, Kearney HM, Monaghan KG, Rehder CW, Chao EC, et al. Points to consider in the reevaluation and reanalysis of genomic test results: a statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2019;21:1267–70.

    Article  PubMed  PubMed Central  Google Scholar 

  11. El Mecky J, Johansson L, Plantinga M, Fenwick A, Lucassen A, Dijkhuizen, et al. Reinterpretation, reclassification, and its downstream effects: challenges for clinical laboratory geneticists. BMC Med Genom. 2019;12:170.

    Article  Google Scholar 

Download references


This paper did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations



SvdC and AAMW designed and wrote the manuscript; SM, ACL, JJ, HB, ASA, AR were essential for the discussion on the topic of VUS-es and provided feedback on the manuscript.

Corresponding author

Correspondence to Saskia N. van der Crabben.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

van der Crabben, S.N., Mörner, S., Lundström, A.C. et al. Should variants of unknown significance (VUS) be disclosed to patients in cardiogenetics or not; only in case of high suspicion of pathogenicity?. Eur J Hum Genet 30, 1208–1210 (2022).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links